FDA’s Purple Book Launches Categorization Era For Biosimilars
This article was originally published in The Pink Sheet Daily
Executive Summary
Modeled on “Orange Book” reference guide for small molecule drugs, agency’s new publication will be a repository of exclusivity and interchangeability information.